Original Article
Does the Use of Asthma-Controller Medication in Accordance with Guidelines Reduce the Incidence of Acute Exacerbations and Healthcare Costs?
Suh-Young Lee, Kyungjoo Kim, Yong Bum Park, et al.
Tuberc Respir Dis. 2022;85(1):11-17.   Published online September 3, 2021
Background: In asthma, consistent control of chronic airway inflammation is crucial, and the use of asthma-controller medication has been emphasized. Our purpose in this study is to compare the incidence of acute exacerbation and healthcare costs related to the use of asthma-controller medication. Methods: By using data collected by the National Health Insurance Review and Assessment Service, we compared one-year clinical...
Original Article
Tiotropium Bromide Has a More Potent Effect Than Corticosteroid in the Acute Neutrophilic Asthma Mouse Model
Tai Joon An, Ji Hye Kim, Chan Kwon Park, et al.
Tuberc Respir Dis. 2022;85(1):18-24.   Published online November 2, 2021
Background: Neutrophilic asthma (NeuA) is usually resistant to corticosteroids. Tiotropium bromide (TIO) is a bronchodilator that is used as an add-on therapy to inhaled corticosteroid and long-acting β2 agonist in asthma treatment. However, the role of TIO in NeuA is not fully known. Thus, the aim of this study was to evaluate the effect of TIO on NeuA compared to...
Original Article
Comparison of Two pMDIs in Adult Asthmatics: A Randomized Double-Blind Double-Dummy Clinical Trial
Tae-Hyun Nam, Sung-Yoon Kang, Sang Min Lee, et al.
Tuberc Respir Dis. 2022;85(1):25-36.   Published online November 29, 2021
Background: Only a few studies directly compared the therapeutic efficacy and safety of two pressurized metered-dose inhalers (pMDIs) in asthma. We analyzed the asthma treatment outcomes, safety, and patient preferences using formoterol/beclomethasone (FORM/BDP), a pMDI with extra-fine particles, compared with formoterol/budesonide (FORM/BUD), another pMDI with non-extra-fine particles. Methods: In this randomized, double-blind, double-dummy parallel group study, 40 adult asthmatics were randomized...
Original Article
A Multicenter Study to Identify the Respiratory Pathogens Associated with Exacerbation of Chronic Obstructive Pulmonary Disease in Korea
Hyun Woo Lee, Yun Su Sim, Ji Ye Jung, et al.
Tuberc Respir Dis. 2022;85(1):37-46.   Published online October 20, 2021
Background: Although respiratory tract infection is one of the most important factors triggering acute exacerbation of chronic obstructive pulmonary disease (AE-COPD), limited data are available to suggest an epidemiologic pattern of microbiology in South Korea. Methods: A multicenter observational study was conducted between January 2015 and December 2018 across 28 hospitals in South Korea. Adult patients with moderate-to-severe acute exacerbations of...
Original Article
The Long-term Efficacy of Domiciliary Noninvasive Positive-Pressure Ventilation in Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials
So Young Park, Kwang Ha Yoo, Yong Bum Park, et al.
Tuberc Respir Dis. 2022;85(1):47-55.   Published online November 15, 2021
Background: We evaluated the long-term effects of domiciliary noninvasive positive-pressure ventilation (NIPPV) used to treat patients with chronic obstructive pulmonary disease (COPD). Methods: Databases were searched to identify randomized controlled trials of COPD with NIPPV for longer than 1 year. Mortality rates were the primary outcome in this meta-analysis. The eight trials included in this study comprised data from 913 patients. Results:...
Original Article
Developing a Diagnostic Bundle for Bronchiectasis in South Korea: A Modified Delphi Consensus Study
Hayoung Choi, Hyun Lee, Seung Won Ra, et al.
Tuberc Respir Dis. 2022;85(1):56-66.   Published online November 15, 2021
Background: Because the etiologies of bronchiectasis and related diseases vary significantly among different regions and ethnicities, this study aimed to develop a diagnostic bundle for bronchiectasis in South Korea. Methods: A modified Delphi method was used to develop expert consensus statements on a diagnostic bundle for bronchiectasis in South Korea. Initial statements proposed by a core panel, based on international bronchiectasis...
Original Article
Efficacy of Roflumilast in Bronchiectasis Patients with Frequent Exacerbations: A Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial
Siwasak Juthong, Pattaraporn Panyarath
Tuberc Respir Dis. 2022;85(1):67-73.   Published online August 3, 2021
Background: Bronchiectasis patients with neutrophilic airway inflammation develop symptoms of chronic cough, sputum production, and recurrent exacerbations. Roflumilast has anti-inflammatory actions via decreased neutrophilic airway inflammation. The effectiveness of roflumilast to reduce bronchiectasis exacerbation has never been evaluated. Methods: We conducted a double-blinded, randomized, placebo-controlled trial. Our primary objective was to assess the effect of roflumilast compared with that of a...
Original Article
Pulmonary Infection
Chronic Obstructive Pulmonary Disease Is Not Associated with a Poor Prognosis in COVID-19
Youlim Kim, Tai Joon An, Yong Bum Park, et al.
Tuberc Respir Dis. 2022;85(1):74-79.   Published online November 15, 2021
Background: The effect of underlying chronic obstructive pulmonary disease (COPD) on coronavirus disease 2019 (COVID-19) during a pandemic is controversial. The purpose of this study was to examine the prognosis of COVID-19 according to the underlying COPD. Methods: COVID-19 patients were assessed using nationwide health insurance data. Comorbidities were evaluated using the modified Charlson Comorbidity Index (mCCI) which excluded COPD from...
Original Article
Pulmonary Infection
Association between Inhaled Corticosteroid Use and SARS-CoV-2 Infection: A Nationwide Population-Based Study in South Korea
Sang Chul Lee, Kang Ju Son, Chang Hoon Han, et al.
Tuberc Respir Dis. 2022;85(1):80-88.   Published online November 30, 2021
Background: Although it is known that inhaled corticosteroid (ICS) use may increase the risk of respiratory infection, its influence on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains unknown. Thus, the aim of this study was to investigate the association between ICS use and the positivity of SARS-CoV-2 infection among patients with chronic respiratory diseases. Methods: Nationwide...
Original Article
Head-to-Head Comparison between Xpert MTB/RIF Assay and Real-Time Polymerase Chain Reaction Assay Using Bronchial Washing Specimens for Tuberculosis Diagnosis
Eunjeong Son, Jinook Jang, Taehwa Kim, et al.
Tuberc Respir Dis. 2022;85(1):89-95.   Published online November 2, 2021
Background: With the introduction of Xpert MTB/RIF assay (Xpert), its incorporation into tuberculosis (TB) diagnostic algorithm has become an important issue. The aim of this study was to evaluate the performance of the Xpert assay in comparison with a commercial polymerase chain reaction (PCR) assay. Methods: Medical records of patients having results of both Xpert and AdvanSure TB/NTM real-time PCR (AdvanSure)...
Original Articles
Afatinib Mediates Autophagic Degradation of ORAI1, STIM1, and SERCA2, Which Inhibits Proliferation of Non–Small Cell Lung Cancer Cells
Mi Seong Kim, So Hui Kim, Sei-Hoon Yang, Min Seuk Kim
Received July 6, 2021   Accepted October 24, 2021   Published online December 1, 2021   
DOI: https://doi.org/10.4046/trd.2021.0095    [Epub ahead of print]
Assessment of Household Catastrophic Total Cost of Tuberculosis and Its Determinants in Cairo: Prospective Cohort Study
Manar M. Ellaban, Nashwa I. Basyoni, Dina N. K. Boulos, Mervat Rady, Mohsen Gadallah
Received February 16, 2021   Accepted September 1, 2021   Published online September 3, 2021   
DOI: https://doi.org/10.4046/trd.2021.0028    [Epub ahead of print]
Full textFull text    PubreaderPubReader    ePubePub    CrossRef-TDMCrossref - TDM    PDFPDF    PDFSupplementary Material

Tuberculosis and
Respiratory Diseases

Print ISSN: 1738-3536
Online ISSN: 2005-6184

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2022 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next
Close layer
prev next